Agilent Technologies, Inc. (NYSE:A) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC reduced its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 748,200 shares of the medical research company’s stock after selling 55,720 shares during the quarter. Champlain Investment Partners LLC’s holdings in Agilent Technologies were worth $100,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the stock. CKW Financial Group raised its holdings in shares of Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Global X Japan Co. Ltd. lifted its holdings in Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 116 shares in the last quarter. Redwood Park Advisors LLC acquired a new stake in shares of Agilent Technologies during the 4th quarter worth about $27,000. Lee Danner & Bass Inc. purchased a new stake in shares of Agilent Technologies during the fourth quarter worth about $29,000. Finally, Hanson & Doremus Investment Management raised its position in shares of Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after buying an additional 105 shares during the last quarter.

Agilent Technologies Price Performance

Shares of NYSE A opened at $102.80 on Thursday. The company has a market capitalization of $29.31 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 2.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $155.35. The business has a 50-day moving average of $121.16 and a 200-day moving average of $133.12.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The company had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. On average, equities analysts anticipate that Agilent Technologies, Inc. will post 5.55 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s payout ratio is 22.76%.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,638 shares of company stock worth $731,229.

Analysts Set New Price Targets

A has been the subject of several recent analyst reports. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Robert W. Baird reduced their target price on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Citigroup raised their price target on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. TD Cowen increased their price objective on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Finally, Barclays lowered their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $146.25.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.